Jane Street Group LLC cut its holdings in shares of 23andMe Holding Co. (NASDAQ:ME - Free Report) by 68.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 726,017 shares of the company's stock after selling 1,561,678 shares during the quarter. Jane Street Group LLC owned approximately 2.96% of 23andMe worth $252,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the business. GSA Capital Partners LLP purchased a new position in 23andMe during the third quarter valued at $805,000. FMR LLC grew its position in shares of 23andMe by 24.0% during the third quarter. FMR LLC now owns 993,848 shares of the company's stock valued at $345,000 after purchasing an additional 192,099 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of 23andMe in the second quarter worth about $203,000. AQR Capital Management LLC lifted its position in shares of 23andMe by 145.8% in the second quarter. AQR Capital Management LLC now owns 444,222 shares of the company's stock worth $174,000 after buying an additional 263,468 shares in the last quarter. Finally, Point72 DIFC Ltd purchased a new position in 23andMe during the 2nd quarter valued at approximately $43,000. 36.10% of the stock is currently owned by hedge funds and other institutional investors.
23andMe Price Performance
Shares of NASDAQ ME traded down $0.21 during mid-day trading on Friday, hitting $3.84. 189,678 shares of the company's stock traded hands, compared to its average volume of 242,942. 23andMe Holding Co. has a 1 year low of $2.65 and a 1 year high of $16.52. The company's 50-day moving average is $3.62 and its two-hundred day moving average is $5.79. The company has a market capitalization of $100.29 million, a P/E ratio of -0.15 and a beta of 1.14.
23andMe (NASDAQ:ME - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($2.32) earnings per share for the quarter. The company had revenue of $44.07 million for the quarter, compared to the consensus estimate of $50.30 million. 23andMe had a negative net margin of 318.39% and a negative return on equity of 129.98%.
About 23andMe
(
Free Report)
23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
Read More
Before you consider 23andMe, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 23andMe wasn't on the list.
While 23andMe currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
